Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate Efficacy and Safety of BI 695500 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma

NCT02417129 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02417129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02417129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate Efficacy and Safety of BI 695500 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2015
Completion date
December 31, 2015
Enrollment
2 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin